Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 217,552,000	$ 139,065,000
Short-term marketable securities (amortized cost of $295,689 and $214,115, respectively)	290,527,000	213,996,000
Accounts receivable, net	26,549,000	17,409,000
Inventory	17,345,000	19,263,000
Prepaid expenses and other current assets	12,407,000	13,015,000
Total current assets	564,380,000	402,748,000
Long-term assets
Property and equipment, net	86,662,000	85,262,000
Operating lease right-of-use assets	82,605,000	87,678,000
Long-term marketable securities (amortized cost of $20,507 and $218,163, respectively)	19,698,000	217,145,000
Restricted cash	2,433,000	2,138,000
Intangible assets, net	7,256,000	8,526,000
Goodwill	118,972,000	118,972,000
Other assets	2,202,000	875,000
Total assets	884,208,000	923,344,000
Current liabilities
Accounts payable	4,163,000	3,307,000
Accrued liabilities	10,702,000	9,343,000
Accrued compensation and benefits	12,733,000	15,642,000
Current portion of operating lease liabilities	8,528,000	5,055,000
Current portion of deferred revenue	67,892,000	80,460,000
Total current liabilities	104,018,000	113,807,000
Long-term liabilities
Operating lease liabilities, less current portion	100,521,000	106,685,000
Deferred revenue, less current portion	67,300,000	98,750,000
Revenue interest liability, net	124,555,000
Total liabilities	396,394,000	319,242,000
Commitments and contingencies (Note 9)
Shareholders’ equity
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021
Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2022 and December 31, 2021; 142,987,127 and 141,393,865 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	14,000	14,000
Additional paid-in capital	1,372,751,000	1,324,006,000
Accumulated other comprehensive loss	(5,971,000)	(1,137,000)
Accumulated deficit	(878,954,000)	(718,891,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity	487,840,000	603,992,000
Noncontrolling interest	(26,000)	110,000
Total shareholders’ equity	487,814,000	604,102,000
Total liabilities and shareholders’ equity	$ 884,208,000	$ 923,344,000